Sunitinib, an inhibitor of kinases, including VEGFR and PDGFR, efficiently induces apoptosis in vitro in glioblastoma (GBM) cells, but does not show any survival benefit in vivo. One detrimental aspect of current in vitro models is that they do not take into account the contribution of extrinsic factors to the cellular response to drug treatment.
Introduction
Several strategies have emerged to attempt to inhibit chemoresistance, but the fact remains that resistance is a problem for every effective anticancer drug (1) . One of the most challenging problems facing cancer researchers is the lack of correlation between in vitro cell lines and animal tumor models and human in vivo tumors (2) . In line with this, sunitinib, a direct inhibitor of the tyrosine-kinase activities of VEGFR, PDGFR and other related kinases (3) , has been shown to induce apoptosis in vitro in glioblastoma (GBM) cells. However, it did not show any survival benefit in GBM xenograft models and its clinical success against GBM is not clear yet (4) . A number of cell culture platforms have been developed in recent years to improve predictivity and further to elucidate the mechanisms governing the differing responses observed in vitro versus in vivo. Despite their importance for drug testing, in vitro methods are beset by pitfalls and inherent limitations (5) . However, given that it is practically impossible to test large quantities of new anticancer agents in vivo, cell culture conditions that mimic the niche of tumor cells need to be further investigated. It is anticipated that the development of in vitro systems representative of tumor microenvironment will lead to an increase in the quality of and reduction in the timelines and costs associated with screening drugs, and enhancement in efficacy information for regulatory decisions. Current in vitro models do not take into account the contribution of different extrinsic factors on the responsiveness of the cells to drug treatment (6) . It has been shown for breast cancer cell lines, that culture within a 3-dimensional (3D) environment decreased taxolinduced cell death (6) . Additionally, several lines of evidence indicate that extracellular matrix-derived biomechanical properties, including extracellular matrix components and matrix rigidity, regulate proliferation and migration of GBM cells (7, 8) . GBM is a highly aggressive tumor that invades the surrounding tissue and leads to regrowth of a recurrent tumor, which is not significantly altered by radiation or chemotherapy (9) . The identification of GBM stem-like cells (GSCs), which are considered to be the cause of tumor formation and recurrence, provided a promising cellular target for more effective therapies against GBM (10) . Although cancer stem-like cells are predicted to be more resistant to chemotherapy and radiation therapy than the other surrounding cancer cells, the susceptibility of GSCs to chemotherapeutic drugs is controversial as the existing literature presents conflicting experimental data (11) . This is likely because the in vitro models used do not recapitulate extrinsic factors of the niche where GSCs reside, which are needed for these cells to maintain their stem cell features (12). Thus, a systematic study of the contribution of different environmental properties to the chemoresponse of
GSCs is yet to come. That study will help develop robust in vitro models of GSCs and will be of clinical importance for the discovery of effective treatments against this deadly disease. In this work, we have analyzed the effects of biophysical and biochemical properties of the substrate on the response of GSCs to an array of chemotherapeutic agents used in the clinic or under clinical trials in cancer patients. Primary cell cultures. Cell cultures from tissue specimens used in this study (GBM and mesenchymal stem-like cells) have been previously characterized and described by our group (8, 13, 14) . The stem-like origin of the cells was tested by analyzing the patterns of differentiation just prior to their use (13, 14) . GSCs were maintained in serum-free DMEM/F12 medium (Life Technologies) containing 20 ng/ml EGF, 20 ng/ml bFGF (both from Sigma-Aldrich), 2 μg/ml heparin and B-27 (20 μl per ml of medium; Invitrogen, Carlsbad, CA) and plated at a density of 3x10 6 live cells/60-mm plate. Primary neurospheres were enzimatically dissociated (acutase; Sigma-Aldrich) every 4-5 days to facilitate cell growth. To promote differentiation, neurospheres were cultured in the same medium but in the presence of 10% (v/v) FBS for four days (14) .
Materials and Methods

Anti
All primary cells were used at low (<20) passage number and seeded at 30.000 cells per cm 2 for cytotoxicity analysis.
Cell culture on 3D matrices. Bovine skin collagen I (PureCol 5005-B, Nutacon BV, Leimuiden, The Netherlands) was prepared at 1.7 mg/ml in HEPES pH 7.3 buffer with serum-and phenol-free DMEM as described (8) and allowed to polymerize at 37 o C for Immunofluorescence analysis. Cells were assayed for the expression of GFAP and Ki67 by fluorescence microscopy as described previously (14) . Briefly, cells were fixed Quantitative RT-PCR. Total RNA was extracted by using a TRI Reagent solution (Sigma-Aldrich). To assess the expression of individual genes, a cDNA was generated and amplified by using primers for human GFAP and β-Actin (8). Quantitative realtime PCR was performed in a 7000 Sequence Detection System (Life Technologies) as described (8) .
Statistical analysis. All statistics were calculated with the SPSS statistical package (version 13.0). Data are presented as mean ± S.D. Differences between groups were tested for statistical significance using the unpaired 2-tailed Student's t test.. The significance level was set at p<0.05.
Results
Response of GBM cell lines to different chemotherapeutic agents.
We first studied the sensitivity of nine different GBM cell lines, cultured on plastic surfaces, to genotoxic drugs (carmustine and cisplatin), inhibitors of anti-apoptotic Bcl-9 lines. Among the CDK inhibitors, 1 μM flavopiridol was more effective than 15 μM roscovitine. However, roscovitine drastically increased its killing activity when combined with ABT-737 or obatoclax in DKMG, GAMG and GMS10 cells. The multikinase inhibitor sorafenib promoted a low level of cell death even at concentrations of 30 μM (6 out of 9 cell lines showed a viability higher than 50%), and did not significantly increased its cell death activity in the presence of pan-Bcl inhibitors. On the contrary, another receptor tyrosine kinase inhibitor, sunitinib at 30 μM was very effective as a single agent (6 out 9 cell lines showed a viability in the range of 0-25%) and significantly increased its capacity to induce cell death in combination with obatoclax. Finally, bortezomib showed to be very effective as a single agent in GAMG and GMS10 cells and moderately increased its effectiveness in the presence of pan-Bcl inhibitors. From these data we concluded that sunitinib was the most effective treatment when used as a single agent. We also determined that U87, GAMG, T98 and 42MGBA formed neurospheres when cultured in the absence of serum (Fig. 1B) , similar to those formed by GBM stem-like cells. T98 and 42MGBA, which were two of the most resistant GBM cell lines, were cultured under serum-free conditions and treated with single agents (Fig. 1C) . Cisplatin and ABT-737 were not effective in either cell line.
However, the sensitivity to roscovitine, sorafenib and sunitinib was clearly increased in the absence of serum in both cell lines. Taking into consideration that chemoresistance is a main feature of cancer stem-like cells, our results suggest that stem-like cell culture conditions in standard plastic surfaces may not be a reliable in vitro model to test compounds against this cell population. We also confirmed that sunitinib induced apoptotic cell death, as determined by measuring the proportion of Annexin V(+) and 7-AAD(-) cells following 12h of treatment ( Supplementary Fig. S1A ). Almost 90% of DKMG cells were apoptotic when treated with 10 μM sunitinib. As apoptosis is mostly 
regulated by Bcl-2 family members, we analyzed the expression of anti-apoptotic proteins Mcl-1, Bcl-2 and Bcl-x in all cell lines. Bcl-2 showed the biggest differences in expression among cell lines. However, there was not a clear correlation between the levels of Bcl-2 and the sensitivity to sunitinib in all cell lines (Supplementary Fig. S1B ).
GBM stem-like cells are sensitive to chemotherapeutic agents in a 2D environment.
GSCs are considered to be responsible for tumor regrowth due in part to their resistance to chemotherapy. We studied the response of thirteen samples of GSCs to the same array of compounds used in cell lines, cultured on flat plastic surfaces. Interestingly, most inhibitors of target proteins (roscovitine, flavopiridol, sunitinib and bortezomib)
were lethal for GSCs as single agents (Fig. 2) . Sunitinib alone promoted an almost complete death of the tumor cell population (only one culture showed a viability higher than 25%). Another multikinase inhibitor, sorafenib was not effective when used alone but killed most cells (cell viability of 11 cultures below 25%) when it was combined with the pan-Bcl inhibitor obatoclax. On the contrary, carmustine, a nitrosourea used in the treatment of GBM, promoted a weak cell death response in 11 GSC cultures. We also studied mesenchymal stem cells (MSCs) from bone marrow (2 samples) and cells isolated from the bulk of GBM tumors (tumor parenchymal cells) (13 samples) and found that both cell types were clearly more resistant than GSCs to the same treatments (Fig. 2) . Moreover, the most effective anti-tumor agent against GSCs, sunitinib, induced a heterogeneous response in tumor parenchymal cells, but only one out of thirteen samples showed a strong cell death response (below 25%).
Biophysical features of the substrate in the response of GSCs to sunitinib.
Very recently, it has been shown described that three-dimensional (3D) culture platforms induced alterations of markers of malignancy in a GBM cell line (17) . We studied the decoupled effects of substrate properties such as elasticity, dimensionality and matrix composition to the response of GSCs to chemotherapeutic agents using 2D and 3D platforms (Fig. 3 ). Significant differences in viability between cells cultured in 2D and 3D substrates were obtained following treatment with cisplatin, flavopiridol and sunitinib (Fig. 4A) . Notably, we observed the highest difference in response to sunitinib. This multikinase inhibitor decreased cell viability to less than 5% on collagencoated surfaces, whereas the proportion of viable cells in 3D collagen matrices was about 50%. Sunitinib-induced cell death was due to apoptosis as determined by analyzing the cleavage of PARP (Fig. 4B) . Consistently, PARP cleavage was more evident in cells cultured on a 2D substrate than in cells incubated in a 3D matrix. In order to analyze whether this dimensionality-dependent response to sunitinib was specific for GSCs, we treated sunitinib-sensitive and sunitinib-resistant GBM parenchymal cells with increasing concentrations of the kinase inhibitor in 2D and 3D environments (Fig. 4C) . In sensitive cells, viability decreased at similar rates both in 2D and 3D substrates whereas in resistant cells a 3D environment provided a significant protection against sunitinib compared with 2D conditions only at a concentration 3-times higher than that used in GSCs. These results suggest that a 3D environment is more critical for the survival of GSCs than for the viability of GBM tumor cells.
Nevertheless, the comparison of 2D and 3D models may be influenced by differences in stiffness. Thus, we studied the influence of substrate elasticity on the response of GSCs to sunitinib. As a 2D environment we used a non-permeable collagen-coated polyacrylamide hydrogel of different stiffness, from 1 kPa (approximately the elastic modulus of brain tissue) to 55 kPa (more than four times stiffer than skeletal muscle), and found that sunitinib was equally effective at killing cells at any of the elasticity coefficients (Fig. 5A) . A 3D environment of different elastic conditions was created by glycation of collagen, which allows up to a fourfold increase in the stiffness of collagen matrices without significant modification to the collagen architecture (15) . Again, no significant differences in cell viability were observed between the different elasticity coefficients (Fig. 5B) . Finally, in order to analyze the contribution of substrate composition, we used matrices made of collagen and hyaluronic acid at different ratios.
As shown in Fig. 5C , even collagen: HA ratios of 1:8 did not significantly modify sunitinib-mediated cell death in comparison with collagen-only matrices. The same result was obtained using either low or high molecular weight HA. Therefore, our data indicate that substrate stiffness and changes in weight ratios of collagen and hyaluronic acid do not modity the response of GSCs to sunitinib.
MEK-ERK and PI3K-Akt pathways contribute to preserve the resistance of GSCs to sunitinib in 3D collagen matrices.
In order to see whether dimensionality was able to modify biological features other than cell survival, we cultured GSCs in 2D or 3D collagen substrates and determined the proliferation rate. Following four days of incubation, the number of proliferating cells was similar in both conditions as determined by Ki67 immunofluorescence staining ( Supplementary Fig. S2A,B) and by counting the number of cells over time ( Supplementary Fig. S2C ). We also showed that the differentiation pattern of GSCs was similar in both 2D and 3D conditions as determined by immunofluorescence staining of the astrocytic marker GFAP (Supplementary Fig. S2D ) and quantitative analysis of the mRNA levels of GFAP (Supplementary Fig. S2E ).
Next we aimed at determining how GSCs sense their physical environment under 3D conditions. The major receptors of extracellular matrix are integrins. The β1 integrin subfamily mediates cell interactions with different extracellular components, including collagen, and it has been shown to regulate chemoresistance of cancer cells (18) . Cells were incubated in 3D matrices in the presence or in the absence of a β1 integrin (Fig. 6A) .
However, blockade of β1 integrin did not significantly modify the cell viability of GSCs after treatment with sunitinib (Fig. 6B) .
Activation of ERK1/2 has been shown to be associated with resistance to cytotoxic agents in cells exposed to collagen (19) . We treated cells with 1 μM PD98059, an inhibitor of MEK1/2 which is an upstream activator of ERK1/2. Treatment with the inhibitor significantly decreased the phosphorylation of both ERK proteins although pERK1 showed a stronger (about 8-fold) reduction (Fig. 6C) . Interestingly, although MEK1/2 inhibitor did not affect viability of GSCs, it drastically decreased (more than 3-fold) cell viability when co-treated with sunitinib (Fig. 6D ). Adhesion to collagen may also activate the PI3kinase-Akt pathway (20) . Thus, we inhibited the pathway by treating cells with 1 μM LY294002 as assessed by downregulation of phosphorylated Akt (Fig. 6C) , and found a clear reduction of cell viability only when combined with sunitinib (Fig. 6D) . However, incubation of cells in the presence of 20 μM AG490, an inhibitor of Stat3, which is a signal transducer relevant in many cancer models, did not modify the response to sunitinib (Fig. 6C, D) . Treatment of GSCs with any of these inhibitors alone did not produce a significant reduction of cell viability (85-100% viable cells) either in 2D or 3D systems (Fig 6D and data not shown) . Other inhibitors that share some kinase targets with sunitinib such as BIBF1120 (Vargatef) and Imatinib (Gleevec) (21), were also less effective at inducing cell death in 3D than in 2D substrates (Fig. 6E) . All three inhibitors target PDGFR. Silencing with specific shRNAs reduced the expression of PDGFRα (about 40%) but did not modify the levels of other related genes (Supplementary Fig. S3A ). However, this reduction did not promote an increase in cell death ( Supplementary Fig. S3B and S3C ). 
Discussion
Cancer stem cells play a major role in sustaining tumor growth. Thus, targeting this rare cell population has become a challenge for researchers. However, the in vitro conditions used in most studies do not allow a good correlation between in vitro and in vivo models of chemotherapy response (4, 22, 23) . Among the different compounds used in this work, sunitinib was the most effective against GBM cell lines and tumor parenchymal cells isolated from GBM patients. This is in agreement with previous studies showing that sunitinib was the only receptor tyrosine kinase inhibitor, among eleven compounds, that could induce apoptosis in GBM cells (4) . GSCs cultured as neurospheres maintain genomic and phenotypic changes of the primary tumor better than traditional cell lines (24) . Interestingly, the cell death response of GSC-containing neurospheres to most compounds tested, including sunitinib, was clearly stronger than that of parenchymal cells, which does not fit with the chemoresistance that characterizes GSCs (11) . In order to shed light on these contradictory data we analyzed different properties of the in vitro microenvironment. This experimental approach is based on the relevance that the environment plays in regulating migration, proliferation and apoptosis of cancer stem cells (8, 12) . It has been shown that mechanical rigidity of the extracellular matrix contributes to key GBM cell properties, including migration and proliferation (7) . However, differences in the stiffness of collagen-based substrates did not promote changes in the response to sunitinib. Microenvironment rigidity has been associated with the response of cancer cells to certain apoptotic stimuli (25, 26) , which may rely on signaling pathways that regulate actomyosin contractility. However, GSCs The effect of dimensionality on chemoresponsiveness could be partly explained in the tumor by the high cell density within the tissue, which may reduce drug penetration.
However, cell density did not modify the observed response to sunitinib in our 3D cell system (data not shown). Alternatively, the spatial organization of a cell within a 3D microenvironment could modulate cell fate decisions such as survival, as previously suggested (32) . Other multikinase inhibitors such as vargatef and imatinib gave similar results to sunitinib. All three inhibitors have a common kinase target, PDGFR. It has been shown that blockade of PDGFR impairs the ability of embryonic stem cells to assemble 3D extracellular matrix, most likely due to decreased expression of matrix proteins including collagen and fibronectin (33) . However, we show that 
